HC Wainwright & Co. Reiterates Buy on Hemab Therapeutics Hldgs, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.2%

Neg 0% Neu 89.2% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and maintains $40 price target.